Resources Repository
-
BookPublication 2014Decision Making in Health and Medicine: Integrating Evidence and Values
Decision making in health care involves consideration of a complex set of diagnostic, therapeutic and …
Decision making in health care involves consideration of a complex set of diagnostic, therapeutic and prognostic uncertainties. Medical therapies have side effects, surgical interventions may lead to complications, and diagnostic tests can produce misleading results. Furthermore, patient values and service costs must be considered. Decisions in clinical and health policy require careful weighing of risks and benefits and are commonly a trade-off of competing objectives: maximizing quality of life vs maximizing life expectancy vs minimizing…
Government/Law | Europe | Probability/Bayes | Preferences/Values | Costing Methods | Health Outcomes | Test Performance | Value of Information | Mathematical Models | Decision Analysis | Cost-Effectiveness Analysis | Health Systems | Economics/Finance | Health/Medicine | Global | North America | Graduate | Doctoral | Professional | Critical Thinking/Analysis | Decision Making/Leadership | Quantitative Literacy -
Resource PackPublication, Teaching Resource 2020Resource Pack: Cost-Effectiveness of SSB Excise Taxes
The use of fiscal instruments, such as taxes or subsidies, to promote healthier dietary behavior …
The use of fiscal instruments, such as taxes or subsidies, to promote healthier dietary behavior has been of increasing interest in the last decade as the evidence-base builds for the health and economic consequences of obesity, overweight, and unhealthy eating. The motivation for using fiscal instruments in nutrition policy is to make the unhealthy option less affordable and less economically attractive by increasing the price via a tax, and therefore reduce the incentive to consume…
Government/Law | Europe | Health Outcomes | Evidence Synthesis | Mathematical Models | Microsimulation | Cost-Effectiveness Analysis | Child/Nutrition | Chronic Disease/Risk | Policy/Regulation | Business/Industry | Economics/Finance | Food/Agriculture | Health/Medicine | North America | Latin America & Caribbean | Oceania -
OrganizationWeb Portal 2024Institute for Clinical and Economic Review (ICER)
ICER is a non-profit organization that evaluates evidence on a range of topics including the value …
ICER is a non-profit organization that evaluates evidence on a range of topics including the value of medical tests, treatments and delivery system innovations and moves that evidence into action to improve the health care system. To accomplish this goal ICER performs analyses on effectiveness and costs, supports specific programs, and develops reports using innovative methods that make it easier to translate evidence into decisions that can align efforts to use evidence to drive improvements in both…
Government/Law | Europe | Preferences/Values | Priority Setting/Ethics | Evidence Synthesis | Value of Information | Cost-Effectiveness Analysis | Technology Assessment | Infectious Diseases | Chronic Disease/Risk | Mental Health | Health Systems | Business/Industry | Economics/Finance | Health/Medicine | Science/Technology | North America -
Resource PackPublication, Teaching Resource 2017Resource Pack: CEA Herpes Zoster Vaccine
This resource pack on the cost-effectiveness of herpes zoster vaccination was curated to support Dr. …
This resource pack on the cost-effectiveness of herpes zoster vaccination was curated to support Dr. Lisa Prosser's seminar on November 9, 2017 at the Center for Health Decision Science. Dr. Prosser discussed an economic evaluation of vaccination against herpes zoster. Herpes zoster—more commonly known as shingles—presents a major burden for older Americans but, until recently, the only available vaccine (Zoster Vaccine Live, ZVL) was relatively ineffective past 10 years. A recently approved vaccine–herpes zoster subunit…
Culture/Society | Europe | Preferences/Values | Costing Methods | Health Outcomes | Mathematical Models | Cost-Effectiveness Analysis | Infectious Diseases | Clinical Care | Health/Medicine | Science/Technology | North America -
ArticlePublication 2014Economic Implications of Population Ageing in China & India: Introduction to the Special Issue
In this special issue of The Journal of the Economics of Ageing, we focus on economic …
In this special issue of The Journal of the Economics of Ageing, we focus on economic aspects of population ageing in the world’s two population superpowers: China and India. China and India have been the subject of comparison for many years. Observations about their relative political and economic development abound (see for example Sen, 2013), but little analysis is currently available of their comparative demographic trajectories and the possible economic consequences of the population ageing that they are both undergoing. These demographic…
Government/Law | Asia & Pacific | Costing Methods | Health Outcomes | Chronic Disease/Risk | Health Systems | Policy/Regulation | Economics/Finance | Health/Medicine -
ArticlePublication 2016An Extended CEA of Schizophrenia Treatment in India under Universal Public Finance
This paper evaluates the potential health and financial risk protection effects of a policy of …
This paper evaluates the potential health and financial risk protection effects of a policy of universal public finance (UPF) to treating schizophrenia in India. The study uses the extended cost effectiveness analysis framework across income quintiles. The results show financial protection benefits concentrated in the richest income quintiles, while health gains were concentrated among the poorest. The value of insurance is highest for the poorest income and decreases as the household income increases. In settings…
Culture/Society | Asia & Pacific | Priority Setting/Ethics | Costing Methods | Cost-Effectiveness Analysis | Mental Health | Health Systems | Clinical Care | Economics/Finance | Health/Medicine -
ArticlePublication 2016What Determines HIV Prevention Costs at Scale?
Human immunodeficiency virus (HIV) prevention services for key populations are commonly delivered through NGOs. However, …
Human immunodeficiency virus (HIV) prevention services for key populations are commonly delivered through NGOs. However, funding for HIV prevention remains scarce, and there are growing calls internationally to improve the efficiency of HIV prevention programmes as a key strategy to reach global HIV targets. To date, there is limited evidence on the determinants of costs of HIV prevention delivered through NGOs, and thus, policymakers have little guidance in how best to design programmes that are…
Government/Law | Asia & Pacific | Costing Methods | Cost-Effectiveness Analysis | Infectious Diseases | Health Systems | Global Governance | Economics/Finance | Health/Medicine -
ArticlePublication 2015Benefits of Scaling a Home-Based Neonatal Care Package in Rural India
In 2011, India introduced a home-based newborn care (HBNC) package to be delivered by community …
In 2011, India introduced a home-based newborn care (HBNC) package to be delivered by community health workers across rural areas. The authors estimate the disease and economic burden that could be averted by scaling up the HBNC in rural India using IndiaSim, an agent-based simulation model. Under one scenario, the existing community health worker network begins providing HBNC for rural households without access to home- or facility-based newborn care. In the second scenario, coverage of…
Culture/Society | Asia & Pacific | Costing Methods | Microsimulation | Cost-Effectiveness Analysis | Child/Nutrition | Health Systems | Health/Medicine -
GuidelinesPublication 2014Principles of Good Practice for Budget Impact Analysis
This report provides recommendations for conducting a Budget Impact Analysis from the ISPOR 2012 Budget …
This report provides recommendations for conducting a Budget Impact Analysis from the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force. National regulatory agencies such as the National Institute for Health and Clinical Excellence in England and Wales and the Pharmaceutical Benefits Advisory Committee in Australia, as well as managed care organizations in the United States, now require that companies submit estimates of both the cost-effectiveness and the likely impact of the new health-care…
Government/Law | Europe | Costing Methods | Health/Medicine